Development of Gene Transfer for Induction of Antigen-specific Tolerance.

Abstract:

:Gene replacement therapies, like organ and cell transplantation are likely to introduce neo-antigens that elicit rejection via humoral and/or effector T cell immune responses. Nonetheless, thanks to an ever growing body of pre-clinical studies it is now well accepted that gene transfer protocols can be specifically designed and optimized for induction of antigen-specific immune tolerance. One approach is to specifically express a gene in a tissue with a tolerogenic microenvironment such as the liver or thymus. Another strategy is to transfer a particular gene into hematopoietic stem cells or immunological precursor cells thus educating the immune system to recognize the therapeutic protein as "self". In addition, expression of the therapeutic protein in pro-tolerogenic antigen presenting cells such as immature dendritic cells and B cells has proven to be promising. All three approaches have successfully prevented unwanted immune responses in pre-clinical studies aimed at the treatment of inherited protein deficiencies, e.g. lysosomal storage disorders and hemophilia, and of type I diabetes and multiple sclerosis. In this review we focus on current gene transfer protocols that induce tolerance, including gene delivery vehicles and target tissues, and discuss successes and obstacles in different disease models.

authors

Sack BK,Herzog RW,Terhorst C,Markusic DM

doi

10.1038/mtm.2014.13

subject

Has Abstract

pub_date

2014-04-30 00:00:00

pages

14013

issn

2329-0501

pii

S2329-0501(16)30063-8

journal_volume

1

pub_type

杂志文章
  • Ready for Repair? Gene Editing Enters the Clinic for the Treatment of Human Disease.

    abstract::We present an overview of clinical trials involving gene editing using clustered interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein 9 (Cas9), transcription activator-like effector nucleases (TALENs), or zinc finger nucleases (ZFNs) and discuss the underlying mechanisms. In cancer immunotherapy, g...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章,评审

    doi:10.1016/j.omtm.2020.06.022

    authors: Ernst MPT,Broeders M,Herrero-Hernandez P,Oussoren E,van der Ploeg AT,Pijnappel WWMP

    更新日期:2020-07-03 00:00:00

  • INSPIIRED: A Pipeline for Quantitative Analysis of Sites of New DNA Integration in Cellular Genomes.

    abstract::Integration of new DNA into cellular genomes mediates replication of retroviruses and transposons; integration reactions have also been adapted for use in human gene therapy. Tracking the distributions of integration sites is important to characterize populations of transduced cells and to monitor potential outgrow of...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2016.11.002

    authors: Sherman E,Nobles C,Berry CC,Six E,Wu Y,Dryga A,Malani N,Male F,Reddy S,Bailey A,Bittinger K,Everett JK,Caccavelli L,Drake MJ,Bates P,Hacein-Bey-Abina S,Cavazzana M,Bushman FD

    更新日期:2016-12-18 00:00:00

  • Genetic Engineering and Manufacturing of Hematopoietic Stem Cells.

    abstract::The marketing approval of genetically engineered hematopoietic stem cells (HSCs) as the first-line therapy for the treatment of severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID) is a tribute to the substantial progress that has been made regarding HSC engineering in the past decade. Rep...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章,评审

    doi:10.1016/j.omtm.2017.03.003

    authors: Wang X,Rivière I

    更新日期:2017-03-18 00:00:00

  • Genetic barcode sequencing for screening altered population dynamics of hematopoietic stem cells transduced with lentivirus.

    abstract::Insertional mutagenesis has been associated with malignant cell transformation in gene therapy protocols, leading to discussions about vector security. Therefore, clonal analysis is important for the assessment of vector safety and its impact on patient health. Here, we report a unique approach to assess dynamic chang...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2014.52

    authors: Zanatta DB,Tsujita M,Borelli P,Aguiar RB,Ferrari DG,Strauss BE

    更新日期:2014-11-19 00:00:00

  • Analyzing the Genotoxicity of Retroviral Vectors in Hematopoietic Cell Gene Therapy.

    abstract::Retroviral vectors, including those derived from gammaretroviruses and lentiviruses, have found their way into the clinical arena and demonstrated remarkable efficacy for the treatment of immunodeficiencies, leukodystrophies, and globinopathies. Despite these successes, gene therapy unfortunately also has had to face ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章,评审

    doi:10.1016/j.omtm.2017.10.002

    authors: Biasco L,Rothe M,Büning H,Schambach A

    更新日期:2017-10-05 00:00:00

  • Liposome Lipid-Based Formulation Has the Least Influence on rAAV Transduction Compared to Other Transfection Agents.

    abstract::Recombinant adeno-associated virus (rAAV) vectors are considered ideal vehicles for human gene therapy. Meanwhile, non-viral strategies, such as transfection agents (TAs), have also shown promise to deliver genetic materials, such as siRNA. Transduction with the rAAV vector is performed concurrently with transfection ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2018.04.004

    authors: Guo P,Yu C,Wang Q,Zhang R,Meng X,Feng Y

    更新日期:2018-04-12 00:00:00

  • Syngeneic AAV Pseudo-particles Potentiate Gene Transduction of AAV Vectors.

    abstract::Adeno-associated virus (AAV) vectors have emerged as a safe and efficient gene therapy platform. One complication is that a significant amount of empty particles have always been generated as impurities during AAV vector production. However, the effects of such particles on AAV vector performance remain unclear. Here ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2016.12.004

    authors: Wang Q,Dong B,Pokiniewski KA,Firrman J,Wu Z,Chin MP,Chen X,Liu L,Xu R,Diao Y,Xiao W

    更新日期:2016-12-24 00:00:00

  • Preclinical safety, pharmacokinetics, pharmacodynamics, and biodistribution studies with Ad35K++ protein: a novel rituximab cotherapeutic.

    abstract::Rituximab is a mouse/human chimeric monoclonal antibody targeted toward CD20. It is efficient as first-line therapy of CD20-positive B-cell malignancies. However, a large fraction of treated patients relapse with rituximab-resistant disease. So far, only modest progress has been made in treatment options for rituximab...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.13

    authors: Richter M,Yumul R,Saydaminova K,Wang H,Gough M,Baldessari A,Cattaneo R,Lee F,Wang CH,Jang H,Astier A,Gopal A,Carter D,Lieber A

    更新日期:2016-03-30 00:00:00

  • Lentiviral Hematopoietic Stem Cell Gene Therapy Corrects Murine Pompe Disease.

    abstract::Pompe disease is an autosomal recessive lysosomal storage disorder characterized by progressive muscle weakness. The disease is caused by mutations in the acid α-glucosidase (GAA) gene. Despite the currently available enzyme replacement therapy (ERT), roughly half of the infants with Pompe disease die before the age o...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.04.023

    authors: Stok M,de Boer H,Huston MW,Jacobs EH,Roovers O,Visser TP,Jahr H,Duncker DJ,van Deel ED,Reuser AJJ,van Til NP,Wagemaker G

    更新日期:2020-05-04 00:00:00

  • The Use of Values WNR and GNR to Distinguish between and Diagnose Different Types of Pancreatitis.

    abstract::There is no effective serologic parameter to distinguish different types of pancreatitis now. To distinguish between acute pancreatitis (AP) and acute exacerbations of chronic pancreatitis (CP) and to determine whether fibrosis occurs in CP, we evaluated the ability to produce white blood cells (WBCs), the neutrophil-...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.05.010

    authors: Luo L,Zhang J,Yang J,Zhang H,Tang Y,Yang D,Dong H,Wu Y,Wang H,Ni B,Tian Z

    更新日期:2020-05-22 00:00:00

  • Quantitative, noninvasive, in vivo longitudinal monitoring of gene expression in the brain by co-AAV transduction with a PET reporter gene.

    abstract::In vivo imaging of vector transgene expression would be particularly valuable for repetitive monitoring of therapy in the brain, where invasive tissue sampling is contraindicated. We evaluated adeno-associated virus vector expression of a dopamine-2 receptor (D2R) mutant (D2R80A) by positron emission tomography in the...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2014.16

    authors: Yoon SY,Gay-Antaki C,Ponde DE,Poptani H,Vite CH,Wolfe JH

    更新日期:2014-06-04 00:00:00

  • Urocortin 2 Gene Transfer Improves Glycemic Control and Reduces Retinopathy and Mortality in Murine Insulin Deficiency.

    abstract::Type 1 diabetes affects 20 million patients worldwide. Insulin is the primary and commonly the sole therapy for type 1 diabetes. However, only a minority of patients attain the targeted glucose control and reduced adverse events. We tested urocortin 2 gene transfer as single-agent therapy for insulin deficiency using ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.12.002

    authors: Gao MH,Giamouridis D,Lai NC,Guo T,Xia B,Kim YC,Huu VAN,Skowronska-Krawczyk D,Lantier L,Bhargava R,Hammond HK

    更新日期:2019-12-14 00:00:00

  • rAAVrh74.MCK.GALGT2 Demonstrates Safety and Widespread Muscle Glycosylation after Intravenous Delivery in C57BL/6J Mice.

    abstract::rAAVrh74.MCK.GALGT2 is a surrogate gene therapy that inhibits muscular dystrophy in multiple animal models. Here, we report on a dose-response study of functional muscle GALGT2 expression as well as toxicity and biodistribution studies after systemic intravenous (i.v.) delivery of rAAVrh74.MCK.GALGT2. A dose of 4.3 × ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.10.005

    authors: Zygmunt DA,Xu R,Jia Y,Ashbrook A,Menke C,Shao G,Yoon JH,Hamilton S,Pisharath H,Bolon B,Martin PT

    更新日期:2019-10-21 00:00:00

  • TFEB overexpression promotes glycogen clearance of Pompe disease iPSC-derived skeletal muscle.

    abstract::Pompe disease (PD) is a lysosomal disorder caused by acid α-glucosidase (GAA) deficiency. Progressive muscular weakness is the major symptom of PD, and enzyme replacement therapy can improve the clinical outcome. However, to achieve a better clinical outcome, alternative therapeutic strategies are being investigated, ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.54

    authors: Sato Y,Kobayashi H,Higuchi T,Shimada Y,Ida H,Ohashi T

    更新日期:2016-08-10 00:00:00

  • Development of a real-time imaging system for hypoxic cell apoptosis.

    abstract::Hypoxic regions within the tumor form due to imbalances between cell proliferation and angiogenesis; specifically, temporary closure or a reduced flow due to abnormal vasculature. They create environments where cancer cells acquire resistance to therapies. Therefore, the development of therapeutic approaches targeting...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.9

    authors: Kagiya G,Ogawa R,Hyodo F,Yamashita K,Nakamura M,Ishii A,Sejimo Y,Tominaga S,Murata M,Tanaka Y,Hatashita M

    更新日期:2016-03-02 00:00:00

  • Codon-Optimization of Wild-Type Adeno-Associated Virus Capsid Sequences Enhances DNA Family Shuffling while Conserving Functionality.

    abstract::Adeno-associated virus (AAV) vectors have become one of the most widely used gene transfer tools in human gene therapy. Considerable effort is currently being focused on AAV capsid engineering strategies with the aim of developing novel variants with enhanced tropism for specific human cell types, decreased human sero...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2018.10.016

    authors: Cabanes-Creus M,Ginn SL,Amaya AK,Liao SHY,Westhaus A,Hallwirth CV,Wilmott P,Ward J,Dilworth KL,Santilli G,Rybicki A,Nakai H,Thrasher AJ,Filip AC,Alexander IE,Lisowski L

    更新日期:2018-11-01 00:00:00

  • Clodronate Improves Survival of Transplanted Hoxb8 Myeloid Progenitors with Constitutively Active GMCSFR in Immunocompetent Mice.

    abstract::New methods to produce large numbers of myeloid progenitor cells, precursors to macrophages (MΦs), by maintaining Hoxb8 transcription factor activity1 has reinvigorated interest in MΦ cell therapies. We generated Hoxb8-dependent myeloid progenitors (HDPs) by transducing lineage-negative bone marrow cells with a consti...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2017.08.007

    authors: Lee S,Kivimäe S,Szoka FC

    更新日期:2017-09-07 00:00:00

  • Cre Recombinase Mediates the Removal of Bacterial Backbone to Efficiently Generate rSV40.

    abstract::Gene therapy has been shown to be a feasible approach to treat inherited disorders in vivo. Among the currently used viral vector systems, adeno-associated virus (AAV) vectors are the most advanced and have been applied in patients successfully. An important drawback of non-integrating AAV vectors is their loss of exp...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2018.02.010

    authors: Shi X,Ykema MR,Hazenoot J,Ten Bloemendaal L,Mancini I,Odijk M,de Haan P,Bosma PJ

    更新日期:2018-02-27 00:00:00

  • Transduction Pattern of AAVs in the Trabecular Meshwork and Anterior-Segment Structures in a Rat Model of Ocular Hypertension.

    abstract::Adeno-associated viruses (AAVs) are the vector of choice for gene therapy in the eye, and self-complementary AAVs (scAAVs), which do not require second-strand DNA synthesis, can be transduced into cells of the trabecular meshwork (TM). The scAAV transduction patterns in the anterior segment of normotensive eyes have b...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.06.009

    authors: Lee SH,Sim KS,Kim CY,Park TK

    更新日期:2019-07-10 00:00:00

  • Experimental Variables that Affect Human Hepatocyte AAV Transduction in Liver Chimeric Mice.

    abstract::Adeno-associated virus (AAV) vector serotypes vary in their ability to transduce hepatocytes from different species. Chimeric mouse models harboring human hepatocytes have shown translational promise for liver-directed gene therapies. However, many variables that influence human hepatocyte transduction and transgene e...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.05.033

    authors: Zou C,Vercauteren KOA,Michailidis E,Kabbani M,Zoluthkin I,Quirk C,Chiriboga L,Yazicioglu M,Anguela XM,Meuleman P,High KA,Herzog RW,de Jong YP

    更新日期:2020-06-02 00:00:00

  • Sendai virus, an RNA virus with no risk of genomic integration, delivers CRISPR/Cas9 for efficient gene editing.

    abstract::The advent of RNA-guided endonuclease (RGEN)-mediated gene editing, specifically via CRISPR/Cas9, has spurred intensive efforts to improve the efficiency of both RGEN delivery and targeted mutagenesis. The major viral vectors in use for delivery of Cas9 and its associated guide RNA, lentiviral and adeno-associated vir...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1038/mtm.2016.57

    authors: Park A,Hong P,Won ST,Thibault PA,Vigant F,Oguntuyo KY,Taft JD,Lee B

    更新日期:2016-08-24 00:00:00

  • Laboratory-Scale Lentiviral Vector Production and Purification for Enhanced Ex Vivo and In Vivo Genetic Engineering.

    abstract::Lentiviral vectors (LVs) are increasingly employed in gene and cell therapy. Standard laboratory production of LVs is not easily scalable, and research-grade LVs often contain contaminants that can interfere with downstream applications. Moreover, purified LV production pipelines have been developed mainly for costly,...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.10.009

    authors: Soldi M,Sergi Sergi L,Unali G,Kerzel T,Cuccovillo I,Capasso P,Annoni A,Biffi M,Rancoita PMV,Cantore A,Lombardo A,Naldini L,Squadrito ML,Kajaste-Rudnitski A

    更新日期:2020-10-20 00:00:00

  • Disease Modification by Combinatorial Single Vector Gene Therapy: A Preclinical Translational Study in Epilepsy.

    abstract::Gene therapy has been suggested as a plausible novel approach to achieve seizure control in patients with focal epilepsy that do not adequately respond to pharmacological treatment. We investigated the seizure-suppressant potential of combinatorial neuropeptide Y and Y2 receptor single vector gene therapy based on ade...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.09.004

    authors: Melin E,Nanobashvili A,Avdic U,Gøtzsche CR,Andersson M,Woldbye DPD,Kokaia M

    更新日期:2019-09-18 00:00:00

  • MTBVAC-Based TB-HIV Vaccine Is Safe, Elicits HIV-T Cell Responses, and Protects against Mycobacterium tuberculosis in Mice.

    abstract::The tuberculosis (TB) vaccine MTBVAC is the only live-attenuated Mycobacterium tuberculosis (Mtb)-based vaccine in clinical development, and it confers superior protection in different animal models compared to the current vaccine, BCG (Mycobacterium bovis bacillus Calmette-Guérin). With the aim of using MTBVAC as a v...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2019.01.014

    authors: Broset E,Saubi N,Guitart N,Aguilo N,Uranga S,Kilpeläinen A,Eto Y,Hanke T,Gonzalo-Asensio J,Martín C,Joseph-Munné J

    更新日期:2019-02-07 00:00:00

  • Single AAV-Mediated CRISPR-SaCas9 Inhibits HSV-1 Replication by Editing ICP4 in Trigeminal Ganglion Neurons.

    abstract::Herpes simplex keratitis (HSK) is the most common cause of corneal blindness in developed nations, caused by primary or recurrent herpes simplex virus 1 (HSV-1) infection of the cornea. Latent infection of HSV-1, especially in the trigeminal ganglion (TG), causes recurrence of HSV-1 infection. As antiviral treatment i...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.05.011

    authors: Chen Y,Zhi S,Liang P,Zheng Q,Liu M,Zhao Q,Ren J,Cui J,Huang J,Liu Y,Songyang Z

    更新日期:2020-05-22 00:00:00

  • Transient Chimeric Ad5/37 Fiber Enhances NK-92 Carrier Cell-Mediated Delivery of Oncolytic Adenovirus Type 5 to Tumor Cells.

    abstract::Methods for customizing and improving virus vector tropism are limited. In this study, we introduce a microRNA (miRNA)-regulated molecular method to enhance vector transduction without genome alteration. Based on the importance of adenovirus (Ad) vectors for cancer and gene treatment, we exemplified this technology fo...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.06.010

    authors: Gao J,Zhang W,Mese K,Bunz O,Lu F,Ehrhardt A

    更新日期:2020-06-18 00:00:00

  • Rosuvastatin Enhances VSV-G Lentiviral Transduction of NK Cells via Upregulation of the Low-Density Lipoprotein Receptor.

    abstract::Adoptive natural killer (NK) cell therapy is attaining promising clinical outcomes in recent years, but improvements are needed. Genetic modification of NK cells with a tumor antigen-specific receptor on their surface coupled to intracellular signaling domains may lead to enhanced cytotoxicity against malignant cells....

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2020.03.017

    authors: Gong Y,Klein Wolterink RGJ,Janssen I,Groot AJ,Bos GMJ,Germeraad WTV

    更新日期:2020-03-29 00:00:00

  • Amelioration of Muscle and Nerve Pathology in LAMA2 Muscular Dystrophy by AAV9-Mini-Agrin.

    abstract::LAMA2-related muscular dystrophy (LAMA2 MD) is the most common and fatal form of early-onset congenital muscular dystrophies. Due to the large size of the laminin α2 cDNA and heterotrimeric structure of the protein, it is challenging to develop a gene-replacement therapy. Our group has developed a novel adeno-associat...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2018.01.005

    authors: Qiao C,Dai Y,Nikolova VD,Jin Q,Li J,Xiao B,Li J,Moy SS,Xiao X

    更新日期:2018-01-31 00:00:00

  • AAV8 Gene Therapy for Crigler-Najjar Syndrome in Macaques Elicited Transgene T Cell Responses That Are Resident to the Liver.

    abstract::Systemic delivery of adeno-associated viral (AAV) vectors has been evaluated for the treatment of several liver diseases, including homozygous familial hypercholesterolemia, ornithine transcarbamylase deficiency, and hemophilia. Here, we evaluated this approach for the treatment of Crigler-Najjar syndrome. We administ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2018.10.012

    authors: Greig JA,Calcedo R,Kuri-Cervantes L,Nordin JML,Albrecht J,Bote E,Goode T,Chroscinski EA,Bell P,Richman LK,Betts MR,Wilson JM

    更新日期:2018-12-05 00:00:00

  • Plastin 3 Promotes Motor Neuron Axonal Growth and Extends Survival in a Mouse Model of Spinal Muscular Atrophy.

    abstract::Spinal muscular atrophy (SMA) is a devastating childhood motor neuron disease. SMA is caused by mutations in the survival motor neuron gene (SMN1), leading to reduced levels of SMN protein in the CNS. The actin-binding protein plastin 3 (PLS3) has been reported as a modifier for SMA, making it a potential therapeutic ...

    journal_title:Molecular therapy. Methods & clinical development

    pub_type: 杂志文章

    doi:10.1016/j.omtm.2018.01.007

    authors: Alrafiah A,Karyka E,Coldicott I,Iremonger K,Lewis KE,Ning K,Azzouz M

    更新日期:2018-01-31 00:00:00